+

WO2001062920A3 - Compositions and methods for diagnosis and therapy of malignant mesothelioma - Google Patents

Compositions and methods for diagnosis and therapy of malignant mesothelioma Download PDF

Info

Publication number
WO2001062920A3
WO2001062920A3 PCT/US2001/005702 US0105702W WO0162920A3 WO 2001062920 A3 WO2001062920 A3 WO 2001062920A3 US 0105702 W US0105702 W US 0105702W WO 0162920 A3 WO0162920 A3 WO 0162920A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
diagnosis
therapy
malignant mesothelioma
Prior art date
Application number
PCT/US2001/005702
Other languages
French (fr)
Other versions
WO2001062920A2 (en
Inventor
Martin A Cheever
Alexander Gaiger
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Priority to AU2001247220A priority Critical patent/AU2001247220A1/en
Priority to NZ521430A priority patent/NZ521430A/en
Priority to JP2001562694A priority patent/JP2003524021A/en
Priority to CA002401070A priority patent/CA2401070A1/en
Priority to EP01920134A priority patent/EP1261711A2/en
Publication of WO2001062920A2 publication Critical patent/WO2001062920A2/en
Publication of WO2001062920A3 publication Critical patent/WO2001062920A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed are compositions and methods for the diagnosis and therapy of Wilms' tumor antigen-associated cancers, and in particular, mesotheliomas. In particular embodiments, the invention provides methods, compositions and kits for eliciting immune and T cell response to Wilms' tumor antigen polypeptide-derived antigenic fragments, and methods for the use of such compositions for diagnosis, detection, treatment, monitoring, and/or prevention of human malignant pleural mesothelioma.
PCT/US2001/005702 2000-02-22 2001-02-22 Compositions and methods for diagnosis and therapy of malignant mesothelioma WO2001062920A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2001247220A AU2001247220A1 (en) 2000-02-22 2001-02-22 Compositions and methods for diagnosis and therapy of malignant mesothelioma
NZ521430A NZ521430A (en) 2000-02-22 2001-02-22 Compositions comprising 1-4 antigenic peptide fragments of the Wilms' tumour gene product for treatment or prevention of malignant mesothelioma
JP2001562694A JP2003524021A (en) 2000-02-22 2001-02-22 Compositions and methods for diagnosis and treatment of malignant mesothelioma
CA002401070A CA2401070A1 (en) 2000-02-22 2001-02-22 Compositions and methods for diagnosis and therapy of malignant mesothelioma
EP01920134A EP1261711A2 (en) 2000-02-22 2001-02-22 Compositions and methods for diagnosis and therapy of malignant mesothelioma

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18407000P 2000-02-22 2000-02-22
US60/184,070 2000-02-22

Publications (2)

Publication Number Publication Date
WO2001062920A2 WO2001062920A2 (en) 2001-08-30
WO2001062920A3 true WO2001062920A3 (en) 2002-07-18

Family

ID=22675440

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/005702 WO2001062920A2 (en) 2000-02-22 2001-02-22 Compositions and methods for diagnosis and therapy of malignant mesothelioma

Country Status (6)

Country Link
EP (1) EP1261711A2 (en)
JP (1) JP2003524021A (en)
AU (1) AU2001247220A1 (en)
CA (1) CA2401070A1 (en)
NZ (1) NZ521430A (en)
WO (1) WO2001062920A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9212228B2 (en) 2005-11-24 2015-12-15 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US9512232B2 (en) 2012-05-09 2016-12-06 Ganymed Pharmaceuticals Ag Antibodies against Claudin 18.2 useful in cancer diagnosis

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2318898T3 (en) 1998-07-31 2009-05-01 International Institute Of Cancer Immunology, Inc. TUMOR ANTIGENS BASED ON THE PRODUCT OF GEN WT1 TUMOR SUPPRESSOR.
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030072767A1 (en) * 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
ES2298353T3 (en) 2001-03-22 2008-05-16 International Institute Of Cancer Immunology, Inc. MODIFIED WT1 PEPTIDE.
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
US20050002951A1 (en) * 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells
WO2003028757A1 (en) * 2001-09-28 2003-04-10 Haruo Sugiyama Novel method of inducing antigen-specific t cells
DE10254601A1 (en) * 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Gene products differentially expressed in tumors and their use
KR20130062368A (en) * 2003-11-05 2013-06-12 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Wt1-origin hla-dr-binding antigen peptide
EP2478913A1 (en) * 2003-12-01 2012-07-25 Sloan-Kettering Institute For Cancer Research Synthetic HLA binding peptide analogues and uses thereof
DE102004024617A1 (en) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentially expressed in tumors gene products and their use
US8765687B2 (en) 2005-10-17 2014-07-01 Sloan Kettering Institute For Cancer Research WT1 HLA class II-binding peptides and compositions and methods comprising same
ES2591029T3 (en) 2006-04-10 2016-11-24 Sloan Kettering Institute For Cancer Research WT-1 immunogenic peptides and methods for use
MX2009007008A (en) * 2006-12-28 2009-07-10 Int Inst Cancer Immunology Inc Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same.
HUE027472T2 (en) 2007-02-27 2016-09-28 Int Inst Cancer Immunology Inc A method of activating a T cell and preparing it for use in the method
SG10201508252PA (en) 2010-10-05 2015-11-27 Int Inst Cancer Immunology Inc Method for activating helper t cell
JP6282598B2 (en) 2012-01-13 2018-02-21 メモリアル スローン ケタリング キャンサー センター Immunogenic WT1 peptides and methods of use thereof
NZ746691A (en) 2012-11-13 2020-08-28 Astellas Pharma Inc Agents for treatment of claudin expressing cancer diseases
BR112015013697A2 (en) 2012-12-17 2017-11-14 Univ Osaka method to activate helper t cell
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
CN116253788A (en) 2013-01-15 2023-06-13 纪念斯隆凯特林癌症中心 Immunogenic WT-1 peptides and methods of use thereof
EP2762160A1 (en) * 2013-02-05 2014-08-06 Nitto Denko Corporation Wt1 peptide cancer vaccine composition for mucosal administration

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006602A1 (en) * 1998-07-31 2000-02-10 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01003344A (en) * 1998-09-30 2004-04-21 Corixa Corp Compositions and methods for wt1 specific immunotherapy.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006602A1 (en) * 1998-07-31 2000-02-10 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
EP1103564A1 (en) * 1998-07-31 2001-05-30 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AMIN K.M. ET AL.: "Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma", THE AMERICAN JOURNAL OF PATHOLOGY, vol. 146, no. 2, February 1995 (1995-02-01), pages 344 - 356, XP001053527 *
OHMINAMI H. ET AL.: "HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide", BLOOD, vol. 95, no. 1, 1 January 2000 (2000-01-01), pages 286 - 293, XP002190642 *
OKA Y. ET AL.: "Cancer immunotherapy targeting Wilms' tumor gene WT1 product", JOURNAL OF IMMUNOLOGY, vol. 164, no. 4, 15 February 2000 (2000-02-15), pages 1873 - 1880, XP001004429 *
OKA Y. ET AL.: "Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product", IMMUNOGENETICS, vol. 51, no. 2, 1 February 2000 (2000-02-01), pages 99 - 107, XP000884935, ISSN: 0093-7711 *
WALKER C. ET AL.: "Wilms' tumor suppressor gene expression in rat and human mesothelioma", CANCER RESEARCH, vol. 54, 15 June 1994 (1994-06-15), pages 3101 - 3106, XP002190643 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9212228B2 (en) 2005-11-24 2015-12-15 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US9499609B2 (en) 2005-11-24 2016-11-22 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US9512232B2 (en) 2012-05-09 2016-12-06 Ganymed Pharmaceuticals Ag Antibodies against Claudin 18.2 useful in cancer diagnosis

Also Published As

Publication number Publication date
WO2001062920A2 (en) 2001-08-30
CA2401070A1 (en) 2001-08-30
JP2003524021A (en) 2003-08-12
NZ521430A (en) 2004-04-30
AU2001247220A1 (en) 2001-09-03
EP1261711A2 (en) 2002-12-04

Similar Documents

Publication Publication Date Title
WO2001062920A3 (en) Compositions and methods for diagnosis and therapy of malignant mesothelioma
WO2002006317A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2002089747A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO1997025426A3 (en) Compositions and methods for the treatment and diagnosis of breast cancer
TR200001646T2 (en) Mamaglobin, a secreted breast cancer protein.
WO2002060317A3 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
WO2002016413A8 (en) Cripto tumour polypeptide
AU2001253079A1 (en) Methods, compositions and kits for the detection and monitoring of breast cancer
AU5311901A (en) A gene differentially expressed in breast and bladder cancer and encoded polypeptides
WO2002074156A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2002092001A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002078516A3 (en) Compositions and methods for the therapy and diagnosis of cancer
WO2002057741A3 (en) Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (sclc)
WO2002012328A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO1998045328A3 (en) Compositions and methods for the treatment and diagnosis of breast cancer
AU4347701A (en) Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
WO2002058534A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2003037267A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2001251613A1 (en) Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers
WO1997029199A3 (en) Prostate specific antigen peptides and uses thereof
WO2001018046A3 (en) Ovarian tumor sequences and methods of use therefor
WO2005025497A3 (en) Hpv cd8+ t-cell epitopes
WO2001090152A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2002047613A3 (en) Immunogenic cancer peptides and uses thereof
WO1999065517A3 (en) Therapeutic compositions that produce an immune response by altering the antigen

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 562694

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2401070

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 521430

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2001247220

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001920134

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001920134

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 521430

Country of ref document: NZ

WWW Wipo information: withdrawn in national office

Ref document number: 2001920134

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 521430

Country of ref document: NZ

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载